.avif)
.avif)
Blueprint Medicines Email Format
Biotechnology Research
・
501-1,000 employees
・
Cambridge, MA, USA
Blueprint Medicines is a global biopharmaceutical company developing life-changing medicines for allergy, inflammation, oncology, and hematology conditions with two approved therapies in the U.S. and Europe.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@blueprintmedicines.com
Company Overview
Industry
Biotechnology Research
Founded
2011
Headquarters
Cambridge, MA, USA
Revenue
$500M-$1B
FUNDING Stage
Public
Key Executives
Ariel Hurley (Head of Finance)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Blueprint Medicines?
Blueprint Medicines uses the firstinitiallast format, so Jane Smith would be jsmith@blueprintmedicines.com.
What are Blueprint Medicines' two core therapeutic focus areas?
Blueprint Medicines focuses on allergy/inflammation and oncology/hematology. The company applies its expertise in mast cell and cancer biology to design potent, selective medicines that target the root causes of disease, including systemic mastocytosis and GIST.
How can I find a specific Blueprint Medicines contact for my outreach list?
Since Blueprint Medicines uses a firstinitiallast email pattern at blueprintmedicines.com, you can construct addresses directly once you have a full name. Tools like Clay can also help you verify contacts and enrich your prospect list with titles and roles across Blueprint Medicines' 750-person team.
What is AYVAKIT and which conditions has Blueprint Medicines received FDA approval to treat with it?
AYVAKIT (avapritinib) is Blueprint Medicines' FDA-approved precision therapy indicated for adults with indolent systemic mastocytosis, advanced systemic mastocytosis, and unresectable or metastatic PDGFRA exon 18 mutation-positive GIST. It is the first and only FDA-approved treatment to address the root cause of systemic mastocytosis.
Where is Blueprint Medicines headquartered, and who leads the company in 2026?
Blueprint Medicines is headquartered in Cambridge, MA. Following its acquisition by Sanofi, which was completed in July 2025, Brittany Carroll serves as Head of Blueprint Medicines, a Sanofi company, as of October 2025.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating